Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 29 2025
0mins
Should l Buy ?
Source: Globenewswire
CC-42344 Antiviral Activity: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, showing approximately 1,000-fold greater potency compared to Tamiflu, and is being developed as an oral treatment for both pandemic and seasonal influenza infections.
Concerns Over Avian Influenza Spread: The outbreak of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, with low population immunity observed in the U.S., highlighting the need for effective treatments as avian flu viruses may become resistant to existing antivirals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
